Remdesivir is an antiviral drug designed to treat infectious diseases such as Ebola and SARS. It has not been approved by any drug regulator in the world, but China is beginning clinical trials in humans to determine if it can treat the coronavirus that has killed 427 people and infected more than 20,000.
It will be tested by a medical team from the China-Japan Friendship Hospital in Beijing, and the trial will take place in central Wuhan, where the outbreak started, Bloomberg reported.
Remdesivir will be given to as many as 270 patients with mild to moderate pneumonia caused by the coronavirus.
The first U.S. patient infected with the virus saw his pneumonia improve after he was given remdesivir, Bloomberg reported, but it may have been unrelated to the drug.
Remdesivir is the best hope for treating the virus at the time, as it could take months for any vaccine to be available for human trials, according to Bloomberg.
Read the full article here.
More articles on pharmacy:
Overburdened pharmacists at top retail chains say they worry about patient safety
OptumRx’s drug trends to watch in 2020: 5 things to know
AmerisourceBergen closes PharMEDium unit, cuts 165 job
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
